OLA
ABBV icon

Oliver Luxxe Assets’s AbbVie ABBV Stock Holding History

Oliver Luxxe Assets’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.92M Sell
31,485
-2,145
-6% -$461K 1.16% 25
2026
Q1 		$7.31M Sell
33,630
-7,609
-18% -$1.69M 1.1% 25
2025
Q4 		$9.42M Buy
41,239
+397
+1% +$90.4K 1.43% 12
2025
Q3 		$9.46M Buy
40,842
+2,517
+7% +$513K 1.5% 12
2025
Q2 		$7.11M Buy
38,325
+1,599
+4% +$297K 1.27% 16
2025
Q1 		$7.69M Sell
36,726
-37,099
-50% -$7.21M 1.43% 12
2024
Q4 		$13.8M Buy
73,825
+37,138
+101% +$6.83M 1.22% 14
2024
Q3 		$7.24M Sell
36,687
-492
-1% -$91.8K 1.3% 10
2024
Q2 		$6.38M Buy
37,179
+27
+0.1% +$4.47K 1.35% 17
2024
Q1 		$6.77M Sell
37,152
-293
-0.8% -$50.5K 1.42% 14
2023
Q4 		$5.8M Buy
37,445
+224
+0.6% +$32.7K 1.36% 19
2023
Q3 		$5.55M Buy
37,221
+529
+1% +$77.7K 1.42% 17
2023
Q2 		$4.94M Sell
36,692
-223
-0.6% -$32.7K 1.23% 25
2023
Q1 		$5.88M Sell
36,915
-3,047
-8% -$466K 1.55% 11
2022
Q4 		$6.46M Sell
39,962
-8
-0% -$1.23K 1.8% 7
2022
Q3 		$5.36M Buy
39,970
+644
+2% +$92.4K 1.68% 9
2022
Q2 		$6.02M Buy
39,326
+612
+2% +$93.5K 1.78% 5
2022
Q1 		$6.28M Sell
38,714
-2,278
-6% -$331K 1.59% 7
2021
Q4 		$5.55M Buy
40,992
+447
+1% +$52.8K 1.41% 11
2021
Q3 		$4.37M Buy
40,545
+3,887
+11% +$444K 1.21% 19
2021
Q2 		$4.13M Buy
36,658
+3,018
+9% +$340K 1.13% 22
2021
Q1 		$3.64M Buy
33,640
+3,880
+13% +$415K 1.09% 29
2020
Q4 		$3.24M Buy
29,760
+7,665
+35% +$737K 1.01% 33
2020
Q3 		$1.94M Buy
22,095
+3,620
+20% +$341K 0.72% 52
2020
Q2 		$1.81M Buy
18,475
+950
+5% +$83.6K 0.95% 46
2020
Q1 		$1.38M Buy
+17,525
New +$1.49M 0.86% 47
2019
Q3 		– Sell
-31,583
Closed -$2.25M – 115
2019
Q2 		$2.25M Buy
31,583
+1,113
+4% +$87.5K 1.25% 40
2019
Q1 		$2.46M Sell
30,470
-1,596
-5% -$131K 1.42% 28
2018
Q4 		$2.96M Sell
32,066
-739
-2% -$65K 1.99% 17
2018
Q3 		$3.1M Buy
32,805
+3,022
+10% +$287K 1.76% 23
2018
Q2 		$2.82M Hold
29,783
– – 1.79% 26
2018
Q1 		$2.82M Buy
+29,783
New +$3.27M 1.74% 26

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
CRM
Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Oliver Luxxe Assets's ABBV Position: Q2 2026 in Review

Oliver Luxxe Assets reduced its AbbVie (ABBV) stake by 6.4% in Q2 2026, selling an estimated $461K and leaving 31,485 shares worth $7.92M. The position accounts for 1.16% of the portfolio, ranked #25.

Oliver Luxxe Assets first reported a position in ABBV in Q1 2018 and has held it in 32 quarters since. The position peaked at $13.8M in Q4 2024. 921 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Oliver Luxxe Assets held 31,485 shares of AbbVie worth $7.92M as of Q2 2026.
  • Oliver Luxxe Assets sold 2,145 AbbVie shares in Q2 2026, an estimated $461K.
  • AbbVie made up 1.16% of Oliver Luxxe Assets's portfolio in Q2 2026, its #25 holding.
  • Oliver Luxxe Assets first reported a position in AbbVie in Q1 2018 and has held it in 32 quarters since.
  • Oliver Luxxe Assets's AbbVie position peaked at $13.8M in Q4 2024.
  • 921 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Oliver Luxxe Assets's 13F filing for Q2 2026, filed 9 Jul 2026.